Intra-Cellular Ther Earnings Estimate

ITCI
 Stock
  

USD 58.31  3.08  5.58%   

Many public companies, such as Intra-Cellular Ther, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Intra-Cellular Ther's earnings estimates, investors can diagnose different trends across Intra-Cellular Ther's analyst sentiment over time as well as compare current estimates against different timeframes.
Intra-Cellular Ther is projected to generate -3.46 in earnings per share on the 31st of December 2021. Intra-Cellular Ther earnings estimates module stress-tests analyst consensus about projected Intra-Cellular Ther EPS (Earning Per Share) to derive its highest and lowest estimates based on its historical volatility. Please see Risk vs Return Analysis.
  
Refresh
The current Gross Profit is estimated to increase to about 81.8 M, while Profit Margin is projected to decrease to (3.66) .

Intra-Cellular Ther Earnings Estimation Breakdown

Calculation of earning per share of Intra-Cellular Ther is based on official Zacks consensus of 3 analysts regarding Intra-Cellular Ther future annual earnings. Given the historical accuracy of 70.99%, the future earnings per share of Intra-Cellular Ther is estimated to be -3.46 with the lowest and highest values of -3.53 and -3.32, respectively. Please note that this consensus of annual earnings estimates for Intra-Cellular Ther is an estimate of EPS before non-recurring items and including employee stock options expenses
  Current EPS -3.2
-3.53
Lowest
Expected EPS -3.46
-3.32
Highest

Intra-Cellular Ther Earnings Projection Consensus

Suppose the current estimates of Intra-Cellular Ther's value are higher than the current market price of the Intra-Cellular Ther stock. In this case, investors may conclude that Intra-Cellular Ther is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Intra-Cellular Ther's stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyCurrent EPSEPS Estimate for 31st of December 2021

3

70.99%

-3.2

-3.46

Intra-Cellular Ther Earnings per Share Projection vs Actual

Actual Earning per Share of Intra-Cellular Ther refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Intra-Cellular Ther predict the company's earnings will be in the future. The higher the earnings per share of Intra-Cellular Ther, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Intra-Cellular Ther Estimated Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Intra-Cellular Ther, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Intra-Cellular Ther should always be considered in relation to other companies to make a more educated investment decision.

Intra-Cellular Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact Intra-Cellular Ther's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2022-05-10
2022-03-31-0.92-0.780.1415 
2022-03-01
2021-12-31-0.99-1.05-0.06
2021-11-09
2021-09-30-0.9149-0.95-0.0351
2021-08-09
2021-06-30-0.8083-0.85-0.0417
2021-05-10
2021-03-31-0.7943-0.650.144318 
2021-02-25
2020-12-31-0.8529-0.760.092910 
2020-11-09
2020-09-30-1.0038-0.790.213821 
2020-08-10
2020-06-30-0.8986-0.96-0.0614
2020-05-07
2020-03-31-0.9-0.730.1718 
2020-03-02
2019-12-31-0.7974-0.740.0574
2019-11-05
2019-09-30-0.8131-0.630.183122 
2019-08-07
2019-06-30-0.8684-0.680.188421 
2019-05-08
2019-03-31-0.8764-0.630.246428 
2019-02-27
2018-12-31-0.9091-0.750.159117 
2018-11-07
2018-09-30-0.8386-0.760.0786
2018-08-02
2018-06-30-0.7525-0.680.0725
2018-05-03
2018-03-31-0.6657-0.650.0157
2018-03-01
2017-12-31-0.525-0.56-0.035
2017-11-08
2017-09-30-0.6163-0.530.086314 
2017-08-09
2017-06-30-0.7425-0.410.332544 
2017-05-10
2017-03-31-0.7213-0.620.101314 
2017-03-01
2016-12-31-0.765-0.640.12516 
2016-11-09
2016-09-30-0.8586-0.70.158618 
2016-08-04
2016-06-30-0.785-0.710.075
2016-04-28
2016-03-31-0.78-0.640.1417 
2016-02-25
2015-12-31-0.8567-0.670.186721 
2015-11-05
2015-09-30-0.7-0.91-0.2130 
2015-08-05
2015-06-30-0.72-0.610.1115 
2015-04-30
2015-03-31-0.61-0.72-0.1118 
2015-03-12
2014-12-31-0.37-0.52-0.1540 
2014-11-03
2014-09-30-0.28-0.220.0621 
2014-08-12
2014-06-30-0.24-0.150.0937 
2014-05-05
2014-03-31-0.23-0.170.0626 
2014-03-25
2013-12-31-0.41-0.30.1126 

About Intra-Cellular Ther Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Intra-Cellular Ther earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Intra-Cellular Ther estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Intra-Cellular Ther fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for 2022
Accumulated Retained Earnings Deficit-1.2 B-1.3 B
Earning Before Interest and Taxes EBIT-284.1 M-291.6 M
Earnings per Basic Share(3.50) (3.77) 
Earnings per Diluted Share(3.50) (3.77) 
Price to Earnings Ratio(14.95) (16.13) 
Earnings Before Interest Taxes and Depreciation Amortization EBITDA-283.6 M-291 M
Earnings before Tax-284.1 M-291.6 M
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York. Intra-Cellular Ther operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 512 people.

Intra-Cellular Ther Investors Sentiment

The influence of Intra-Cellular Ther's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Intra-Cellular. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Intra-Cellular Ther Implied Volatility

    
  77.74  
Intra-Cellular Ther's implied volatility exposes the market's sentiment of Intra-Cellular Ther stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Intra-Cellular Ther's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Intra-Cellular Ther stock will not fluctuate a lot when Intra-Cellular Ther's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Intra-Cellular Ther in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Intra-Cellular Ther's short interest history, or implied volatility extrapolated from Intra-Cellular Ther options trading.

Current Sentiment - ITCI

Intra-Cellular Ther Investor Sentiment

Most of Macroaxis users are currently bullish on Intra-Cellular Ther. What is your judgment towards investing in Intra-Cellular Ther? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Intra-Cellular Ther using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Risk vs Return Analysis. Note that the Intra-Cellular Ther information on this page should be used as a complementary analysis to other Intra-Cellular Ther's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.

Complementary Tools for Intra-Cellular Stock analysis

When running Intra-Cellular Ther price analysis, check to measure Intra-Cellular Ther's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intra-Cellular Ther is operating at the current time. Most of Intra-Cellular Ther's value examination focuses on studying past and present price action to predict the probability of Intra-Cellular Ther's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Intra-Cellular Ther's price. Additionally, you may evaluate how the addition of Intra-Cellular Ther to your portfolios can decrease your overall portfolio volatility.
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Is Intra-Cellular Ther's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intra-Cellular Ther. If investors know Intra-Cellular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intra-Cellular Ther listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
5.2 B
Quarterly Revenue Growth YOY
1.2
Return On Assets
-0.25
Return On Equity
-0.43
The market value of Intra-Cellular Ther is measured differently than its book value, which is the value of Intra-Cellular that is recorded on the company's balance sheet. Investors also form their own opinion of Intra-Cellular Ther's value that differs from its market value or its book value, called intrinsic value, which is Intra-Cellular Ther's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intra-Cellular Ther's market value can be influenced by many factors that don't directly affect Intra-Cellular Ther's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intra-Cellular Ther's value and its price as these two are different measures arrived at by different means. Investors typically determine Intra-Cellular Ther value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intra-Cellular Ther's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.